Yüklüyor......
Molecular targeting to treat gastric cancer
Trastuzumab that targets human epidermal growth factor receptor 2 (HER2) protein is the only approved molecular targeting agent for treating gastric cancer in Japan and the outcomes have been favorable. However, trastuzumab is effective for only 10% to 20% of the population with gastric cancer that...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Baishideng Publishing Group Inc
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4194558/ https://ncbi.nlm.nih.gov/pubmed/25320512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i38.13741 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|